Alzheimer¿s Dementia, Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD), Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple Sclerosis, Parkinson¿s Disease, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders. Moreover, the book includes an extensive overview of glutamatergic treatments already available on the market, and those which are currently in pharmaceutical drug development pipelines. The primary beneficiaries will be neurology and psychiatry specialists and residents, neuroscientists, neuropharmacologists, pharmaceutical industry and clinical research organization professionals, academics, and clinicians working with psychiatric and neurological patients with comorbidities such as cardiologists, pulmonologists, and endocrinologists. This book will also appeal to psychiatry and neurology subspecialists and clinicians working in neuroscience labs seeking an easy-to-understand yet comprehensive overview of contemporary evidence-based clinical insights backed by basic science (preclinical) research evidence. Given its scope, the book is also a unique and indispensable resource for both preclinical and clinical neuroscientists, medical advisors, and clinical research specialists in the pharmaceutical industry. In addition, it will appeal to neuroscience and neuropsychopharmacology students and guide them through the complexities of glutamate involvement in the pathophysiology of the most common debilitating brain diseases with high unmet medical needs.